{
  "docId": "019de073-79f3-7749-b6d9-2feecaaa4d92",
  "docSlug": "3bbd721bd246637706dab09d5c4f3165",
  "documentTitle": "Apexigen | Investor Presentation Deck | 27 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 27,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a diagram of an antibody to map specific functional regions to their biological mechanisms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-79f3-7749-b6d9-2feecaaa4d92/10",
  "deckHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92",
  "deckJsonHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92.json",
  "deckAnchorHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.18,
        "x": 0.77,
        "y": 0.15
      },
      "kind": "callout",
      "text": "Sotigalimab: Single-agent efficacy; Synergy with anti-PD-1, chemotherapy, radiation & other therapeutics; Reasonable safety profile; Patent exclusivity until 2032+",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d58e96e-0e53-4da4-b598-52bd2a6a8ddf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "image",
      "text": "Antibody structure diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "559d7d68-496d-4287-b409-1ffe651ceab0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.33,
        "y": 0.6
      },
      "kind": "list",
      "text": "Rationally Designed Fc Mutations: Better Potency: Increased binding to FcyIIbR enhances cross-linking and agonistic signaling; Designed to eliminate FcyIIIaR binding to prevent ADCC effector function and avoid killing APCs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16478796-e90a-4044-9255-7af0839064b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.33,
        "y": 0.28
      },
      "kind": "list",
      "text": "Uniquely Binds to Native Ligand Binding Domain, with High Affinity: Increased potency through binding to CD40L domain, mimicking natural CD40L signaling; Humanized IgG1/k mAb binds to human CD40 with high affinity (Kd = 1.2x10-10M)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7b54377-faa1-4648-9ac9-bbe33d7c996d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Sotiga was Rationally Designed for Potency and to Mimic Natural Ligand",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2b6bafb-dded-4ec7-8a2d-a5cdbb32783e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 9,
      "beatId": "bfa88b56-3bff-4ff7-bf10-cf826d73f1e6",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 9-11 present Sotigalimab as a solution, including its design and differentiation from other CD40 agonists",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "5026d18e-139d-4879-9fd9-ca4f599102e8",
      "evidence": "The solution section presents Sotigalimab as a rationally designed and differentiated CD40 agonist",
      "position": 1,
      "objective": "Why is Sotigalimab a good solution?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}